I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year.
Tag Archives: Cynthia Robbins Roth
Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?
March 15, 2012 – 10:46 am
The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire.
Join the Conversation